TY - JOUR
T1 - Implementation of a pan-genomic approach to investigate holobiont-infecting microbe interaction
T2 - A case report of a leukemic patient with invasive mucormycosis
AU - Shelburne, Samuel A.
AU - Ajami, Nadim J.
AU - Chibucos, Marcus C.
AU - Beird, Hannah C.
AU - Tarrand, Jeffrey
AU - Galloway-Peña, Jessica
AU - Albert, Nathan
AU - Chemaly, Roy F.
AU - Ghantoji, Shashank S.
AU - Marsh, Lisa
AU - Pemmaraju, Naveen
AU - Andreeff, Michael
AU - Shpall, Elizabeth J.
AU - Wargo, Jennifer A.
AU - Rezvani, Katayoun
AU - Alousi, Amin
AU - Bruno, Vincent M.
AU - Futreal, Phillip A.
AU - Petrosino, Joseph F.
AU - Kontoyiannis, Dimitrios P.
N1 - Funding Information:
This work was supported by the National Institutes of Allergy and Infectious Diseases at the National Institutes of Health [R01AI089891 to SAS, U19AI110820 to MCC and VMB, and HHSN272200900009C to VMB], the Chapman Foundation and MD Anderson Cancer Center Support Grant P30 CA016672 (the Bioinformatics Shared Resource), the CFP Foundation supported MDACC Odyssey Fellowship (JGP), the MDACC Moon Shot GAP Proposal (DPK), and the Frances King Black Endowment for Cancer Research (DPK). The authors gratefully acknowledge Shawn Lockhart, PhD for supplying the genomic DNA used for whole genome sequencing of the non-RM1 fungal isolates.
Publisher Copyright:
© 2015 Shelburne et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
PY - 2015/11/10
Y1 - 2015/11/10
N2 - Disease can be conceptualized as the result of interactions between infecting microbe and holobiont, the combination of a host and its microbial communities. It is likely that genomic variation in the host, infecting microbe, and commensal microbiota are key determinants of infectious disease clinical outcomes. However, until recently, simultaneous, multiomic investigation of infecting microbe and holobiont components has rarely been explored. Herein, we characterized the infecting microbe, host, micro-and mycobiomes leading up to infection onset in a leukemia patient that developed invasive mucormycosis. We discovered that the patient was infected with a strain of the recently described Mucor velutinosus species which we determined was hypervirulent in a Drosophila challenge model and has a predisposition for skin dissemination. After completing the infecting M. velutinosus genome and genomes from four other Mucor species, comparative pathogenomics was performed and assisted in identifying 66 M. velutinosus-specific putatively secreted proteins, including multiple novel secreted aspartyl proteinases which may contribute to the unique clinical presentation of skin dissemination. Whole exome sequencing of the patient revealed multiple non-synonymous polymorphisms in genes critical to control of fungal proliferation, such as TLR6 and PTX3. Moreover, the patient had a non-synonymous polymorphism in the NOD2 gene and a missense mutation in FUT2, which have been linked to microbial dysbiosis and microbiome diversity maintenance during physiologic stress, respectively. In concert with host genetic polymorphism data, the micro-and mycobiome analyses revealed that the infection developed amid a dysbiotic microbiome with low α-diversity, dominated by staphylococci. Additionally, longitudinal mycobiome data showed that M. velutinosus DNA was detectable in oral samples preceding disease onset. Our genome-level study of the hostinfecting microbe-commensal triad extends the concept of personalized genomic medicine to the holobiont-infecting microbe interface thereby offering novel opportunities for using synergistic genetic methods to increase understanding of infectious diseases pathogenesis and clinical outcomes.
AB - Disease can be conceptualized as the result of interactions between infecting microbe and holobiont, the combination of a host and its microbial communities. It is likely that genomic variation in the host, infecting microbe, and commensal microbiota are key determinants of infectious disease clinical outcomes. However, until recently, simultaneous, multiomic investigation of infecting microbe and holobiont components has rarely been explored. Herein, we characterized the infecting microbe, host, micro-and mycobiomes leading up to infection onset in a leukemia patient that developed invasive mucormycosis. We discovered that the patient was infected with a strain of the recently described Mucor velutinosus species which we determined was hypervirulent in a Drosophila challenge model and has a predisposition for skin dissemination. After completing the infecting M. velutinosus genome and genomes from four other Mucor species, comparative pathogenomics was performed and assisted in identifying 66 M. velutinosus-specific putatively secreted proteins, including multiple novel secreted aspartyl proteinases which may contribute to the unique clinical presentation of skin dissemination. Whole exome sequencing of the patient revealed multiple non-synonymous polymorphisms in genes critical to control of fungal proliferation, such as TLR6 and PTX3. Moreover, the patient had a non-synonymous polymorphism in the NOD2 gene and a missense mutation in FUT2, which have been linked to microbial dysbiosis and microbiome diversity maintenance during physiologic stress, respectively. In concert with host genetic polymorphism data, the micro-and mycobiome analyses revealed that the infection developed amid a dysbiotic microbiome with low α-diversity, dominated by staphylococci. Additionally, longitudinal mycobiome data showed that M. velutinosus DNA was detectable in oral samples preceding disease onset. Our genome-level study of the hostinfecting microbe-commensal triad extends the concept of personalized genomic medicine to the holobiont-infecting microbe interface thereby offering novel opportunities for using synergistic genetic methods to increase understanding of infectious diseases pathogenesis and clinical outcomes.
UR - http://www.scopus.com/inward/record.url?scp=84953206097&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84953206097&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0139851
DO - 10.1371/journal.pone.0139851
M3 - Article
C2 - 26556047
AN - SCOPUS:84953206097
SN - 1932-6203
VL - 10
JO - PLoS ONE
JF - PLoS ONE
IS - 11
M1 - e0139851
ER -